PMID- 30576255
OWN - NLM
STAT- MEDLINE
DCOM- 20200318
LR  - 20200318
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 19
IP  - 3
DP  - 2019 Mar
TI  - ALK testing methods: is there a winner or loser?
PG  - 237-244
LID - 10.1080/14737140.2019.1562343 [doi]
AB  - Anaplastic lymphoma kinase (ALK) is one of the most attractive molecular targets 
      for the treatment of patients with non-small-cell lung cancer. Treatment with ALK 
      inhibitors is recognized as the standard-of-care for patients with ALK gene 
      rearrangements, but it is important to appropriately select patients who will 
      benefit from such treatment. Areas covered: In this article, we review the 
      evidence regarding ALK testing. Immunohistochemistry (IHC), fluorescence in situ 
      hybridization (FISH), and reverse transcription polymerase chain reaction 
      (RT-PCR) are the representative methods for detecting ALK gene fusions. Among 
      these diagnostic modalities, IHC in particular exhibits high sensitivity and 
      specificity for the detection of ALK fusions when appropriately applied and 
      interpreted. Expert commentary: Discrepancies have been reported between the 
      results of IHC and FISH. However, it was revealed that patients with 
      IHC-positivity and FISH-negativity may respond to alectinib, indicating that IHC 
      can be used as a stand-alone method from a clinical standpoint for the 
      identification of patients eligible for treatment with ALK inhibitors. In 
      addition, differences between ALK variants have been reported to affect the 
      prognosis and efficacy of ALK inhibitor-based treatments, and RT-PCR will likely 
      increase in importance as a complementary tool.
FAU - Kozuma, Yuka
AU  - Kozuma Y
AD  - a Department of Thoracic Oncology , National Kyushu Cancer Center , Fukuoka , 
      Japan.
AD  - b Department of Surgery and Sciences, Graduate School of Medical Sciences , 
      Kyushu University , Fukuoka , Japan.
FAU - Toyokawa, Gouji
AU  - Toyokawa G
AD  - b Department of Surgery and Sciences, Graduate School of Medical Sciences , 
      Kyushu University , Fukuoka , Japan.
FAU - Seto, Takashi
AU  - Seto T
AD  - a Department of Thoracic Oncology , National Kyushu Cancer Center , Fukuoka , 
      Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181228
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/*antagonists & inhibitors/genetics
MH  - Antineoplastic Agents/pharmacology
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/pathology
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*drug therapy/genetics/pathology
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Reverse Transcriptase Polymerase Chain Reaction
OTO - NOTNLM
OT  - ALK
OT  - FISH
OT  - IHC
OT  - RT-PCR
OT  - non-small-cell lung cancer
EDAT- 2018/12/24 06:00
MHDA- 2020/03/19 06:00
CRDT- 2018/12/22 06:00
PHST- 2018/12/24 06:00 [pubmed]
PHST- 2020/03/19 06:00 [medline]
PHST- 2018/12/22 06:00 [entrez]
AID - 10.1080/14737140.2019.1562343 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2019 Mar;19(3):237-244. doi: 
      10.1080/14737140.2019.1562343. Epub 2018 Dec 28.